The incidence and clinical predictors of ACE-inhibitor induced dry cough by perindopril in 27,492 patients with vascular disease

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 718-723

  Brugts, J J ^a   Arima, Hisatomi ^b,c   Remme, W ^d   Bertrand, M ^e   Ferrari, R ^f   Fox, K ^g   Dinicolantonio, J ^h   Macmahon, S ^b,c   Chalmers, J ^b,c   Zijlstra, F ^a   Caliskan, K ^a   Simoons, M L ^a   Mourad, J J ⁱ   Boersma, E ^a   Akkerhuis, K M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Sticares Cardiovascular Research Foundation   (Netherlands)

^e Lille Heart Institute   (France)

^f UNIVERSITY OF FERRARA   (Italy)

^g ROYAL BROMPTON HOSPITAL   (United Kingdom)

^h Mid America Heart Institute Saint Luke's Hospital   (United States)

ⁱ ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

ACE inhibitor; Cough; Intolerance; Perindopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL;

AGE; AGED; CHEMICALLY INDUCED; CONTROLLED STUDY; COUGH; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; VASCULAR DISEASES;

AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COUGH; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERINDOPRIL; PREDICTIVE VALUE OF TESTS; SEX FACTORS; VASCULAR DISEASES;

EID: 84908207158     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.108     Document Type: Article

References (26)

1. M.A. Pfeffer, E. Braunwald, and L.A. Moye SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction and myocardial infarction: results of the survival and ventricular enlargement trial N Engl J Med 327 1992 669 677
2. The SOLVD investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
3. The Acute Infarction Ramipril Efficacy (AIRE) study investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
4. C. Torp-Pedersen, L. Kober, and TRACE Study Group Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction Lancet 354 1999 9 12
5. The Heart Outcomes Prevention Evaluation study investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
6. The PEACE Trial Investigators Angiotensin-converting-enzyme inhibition in stable coronary artery disease N Engl J Med 351 2004 2058 2068
7. The European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease investigators Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study) Lancet 362 2003 782 788
8. J.J. Brugts, R. Ferrari, and M.L. Simoons Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease Expert Rev Cardiovasc 7 4 2009 345 360
9. The task force on the management of stable angina pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris Eur Heart J 27 2006 1341 1381
10. D. Wood, G. DeBacker, and O. Faergam Prevention of coronary disease in clinical practice: recommendation of the second joint task force of European and other societies on coronary prevention Atherosclerosis 140 1998 99 270
11. R.J. Gibbons, J. Abrams, and K. Chatterjee ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina) J Am Coll Cardiol 41 2003 159 168
12. S. Bagalore, S. Kumar, and F.H. Messerli Angiotensin-Converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference Am J Med 123 2012 1016 1030
13. P.V. Dicpinigaitis Angiotensin-converting enzyme induced cough: ACCP evidence-based clinical practice guidelines Chest 129 2006 169S 173S
14. L.E. Visser, B.H. Stricker, and J. van der Velden Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study J Clin Epidemiol 48 1995 851 857
15. R. Wood Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study Br J Clin Pharmacol 39 1995 265 270
16. V. Charlon, S. Dollow, and J. Fidel Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study Br J Clin Pharmacol 39 1995 125 129
17. Direct Thrombin Inhibitors Trialists' Collaborative Group Direct thrombin inhibitors in acute coronary syndromes and during percutaneous coronary intervention: design of a meta-analysis based on individual patient data Am Heart J 141 2001 e2
18. J.J. Brugts, T. Ninomiya, and E. Boersma The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials Eur Heart J 30 2009 1385 1394
19. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
20. PROGRESS Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack Lancet 358 2001 1033 1041
21. L. van Vark, M. Bertrand, and K.M. Akkerhuis Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients Eur Heart J 33 16 2012 2088 2097
22. J.J. Brugts, M.P. de Maat, and E. Boersma The rationale and design of the Perindopril Genetic Association Study (PERGENE): a pharmacogenetic analysis of ACE-inhibitor therapy in Patients with stable coronary artery disease Cardiovasc Drugs Ther 29 2009 171 181
23. J.J. Brugts, C.A. den Uil, and A.H.J. Danser The renin-angiotensin-system: approaches to guide ACE-inhibition in patients with coronary artery disease Cardiology 112 2009 303 312
24. J.J. Brugts, A. Isaacs, and M.P. de Maat A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals J Hypertens 29 2011 509 519
25. I. Liesmaa, J.O. Kokkonen, P.T. Kovanen, and K.A. Lindsteds Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells J Mol Cell Cardiol 43 2007 593 600
26. R.R. Moholissa, B.R. Rayner, and P.E. Owen Association of B2 receptor polymorphisms and ACE activity with ACE-inhibitor induced angioedema and cough in black and mixed-race South Africans J Clin Hypertens 15 2013 413 419